caa a22 4500 445377607 CHVBK 20180317143007.0 cr unu---uuuuu 170323e20110201xx s 000 0 eng 10.1007/s00702-010-0529-x doi (NATIONALLICENCE)springer-10.1007/s00702-010-0529-x Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm [Elektronische Daten] [Bettina Wabbels, Gerhard Reichel, Antony Fulford-Smith, Nicola Wright, Peter Roggenkämper] Botulinum neurotoxins (BoNTs) are the primary treatment for focal dystonias such as blepharospasm. Several different BoNT products are available in various countries. Given the variability in manufacturing, formulation, and unit doses of BoNTs, it is important to compare the profiles of products from different manufacturers. This double-blind, randomised, parallel-group pilot study compared the efficacy and safety of the BoNT type A product Xeomin® from Merz to BOTOX® from Allergan. Subjects (n=65) were randomly assigned to receive one or the other BoNTA in a 1:1 proportion at a dose equal to that of their most recent treatment (≥20U/eye). Symptoms were assessed on the Blepharospasm Disability Index (BSDI), Jankovic Rating Scale (JRS), and Patient Global Assessment (PGA) scale at 4 and 8weeks. Both BoNTA products reduced scores on the BSDI and JRS (no statistically significant difference, tendency toward greater improvements with BOTOX® than Xeomin® at 4 and 8weeks). A post hoc analysis showed a significantly greater number of BOTOX® treated patients reaching a responder threshold of 4 points on the total BSDI score and 0.67 points on the BSDI mean item score. No significant differences between products were noted in PGA and adverse events at the doses used in this study. Springer-Verlag, 2010 Blepharospasm nationallicence Botulinum nationallicence Jankovic Rating Scale nationallicence Blepharospasm Disability Index nationallicence BOTOX® nationallicence Xeomin® nationallicence Wabbels Bettina Department of Ophthalmology, University of Bonn, Abbestr. 2, 53127, Bonn, Germany aut Reichel Gerhard Department of Movement Disorders, Paracelsus-Klinik Zwickau, Zwickau, Germany aut Fulford-Smith Antony Allergan, Ltd., Buckinghamshire, UK aut Wright Nicola Allergan, Ltd., Buckinghamshire, UK aut Roggenkämper Peter Department of Ophthalmology, University of Bonn, Abbestr. 2, 53127, Bonn, Germany aut Journal of Neural Transmission Springer Vienna 118/2(2011-02-01), 233-239 0300-9564 118:2<233 2011 118 702 https://doi.org/10.1007/s00702-010-0529-x text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s00702-010-0529-x text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Wabbels Bettina Department of Ophthalmology, University of Bonn, Abbestr. 2, 53127, Bonn, Germany aut NATIONALLICENCE 700 1- Reichel Gerhard Department of Movement Disorders, Paracelsus-Klinik Zwickau, Zwickau, Germany aut NATIONALLICENCE 700 1- Fulford-Smith Antony Allergan, Ltd., Buckinghamshire, UK aut NATIONALLICENCE 700 1- Wright Nicola Allergan, Ltd., Buckinghamshire, UK aut NATIONALLICENCE 700 1- Roggenkämper Peter Department of Ophthalmology, University of Bonn, Abbestr. 2, 53127, Bonn, Germany aut NATIONALLICENCE 773 0- Journal of Neural Transmission Springer Vienna 118/2(2011-02-01), 233-239 0300-9564 118:2<233 2011 118 702 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer